高剂量与低剂量泼尼松龙治疗新冠后弥漫性肺实质异常的随机试验
COLDSTER试验是一项开放标签随机试验,比较高剂量与低剂量6周泼尼松龙方案在新冠后弥漫性肺实质异常(PC-DPLAS)症状患者中的效果。研究提示高剂量方案在改善临床、生理、影像学结局及健康相关生活质量方面可能并不优于低剂量方案。既往观察性研究曾报告糖皮质激素可改善此类患者,但缺乏随机对照试验证据。
要点
- 高剂量泼尼松龙在改善临床、生理及影像学结局方面可能不优于低剂量6周方案。
- 高剂量方案在健康相关生活质量改善方面也可能不优于低剂量方案。
- 既往观察性研究提示糖皮质激素对PC-DPLAS有效,但本研究为随机对照试验提供新证据。
核心结论
- 高剂量泼尼松龙在改善临床、生理和影像学结局或健康相关生活质量方面可能不优于低剂量6周方案。
研究设计与样本
- 开放标签随机试验(COLDSTER试验),纳入有症状的新冠后弥漫性肺实质异常患者,比较高剂量与低剂量泼尼松龙6周方案。
主要发现
- 高剂量泼尼松龙在改善临床、生理、影像学结局及健康相关生活质量方面可能不优于低剂量6周方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose prednisolone may not be superior to a low-dose 6-week regimen in improving clinical, physiological and radiological outcomes, or health-related quality of life, in patients with symptomatic post-COVID-19 diffuse parenchymal lung abnormalities https://bit.ly/32zqnXt In some patients, respiratory symptoms and imaging abnormalities persist after acute coronavirus disease 2019 (COVID-19) pneumonia [1–3]. Chest computed tomography (CT) scans generally show diffuse parenchymal lung abnormalities consistent with organising pneumonia [4]. It has been proposed that the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could act as a trigger to exalt the presence of pre-existing interstitial lung abnormalities encountered in the general population, especially in smokers. Previous observational studies reported improvement with glucocorticoids in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities (PC-DPLAS) [4–6]. A recent guideline recommended glucocorticoids for treating PC-DPLAS [3]. However, there are no randomised controlled trials on therapies for this condition.
引用
- Dhooria S, Chaudhary S, Sehgal IS, et al. High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial). Eur Respir J. 2022. PMID: 34887325. doi:10.1183/13993003.02930-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。